Nature Communications (Jul 2020)
Molecular engineering of safe and efficacious oral basal insulin
- Frantisek Hubálek,
- Hanne H. F. Refsgaard,
- Sanne Gram-Nielsen,
- Peter Madsen,
- Erica Nishimura,
- Martin Münzel,
- Christian Lehn Brand,
- Carsten Enggaard Stidsen,
- Christian Hove Claussen,
- Erik Max Wulff,
- Lone Pridal,
- Ulla Ribel,
- Jonas Kildegaard,
- Trine Porsgaard,
- Eva Johansson,
- Dorte Bjerre Steensgaard,
- Lars Hovgaard,
- Tine Glendorf,
- Bo Falck Hansen,
- Maja Kirkegaard Jensen,
- Peter Kresten Nielsen,
- Svend Ludvigsen,
- Susanne Rugh,
- Patrick W. Garibay,
- Mary Courtney Moore,
- Alan D. Cherrington,
- Thomas Kjeldsen
Affiliations
- Frantisek Hubálek
- Novo Nordisk A/S, Novo Nordisk Park 1
- Hanne H. F. Refsgaard
- Novo Nordisk A/S, Novo Nordisk Park 1
- Sanne Gram-Nielsen
- Novo Nordisk A/S, Novo Nordisk Park 1
- Peter Madsen
- Novo Nordisk A/S, Novo Nordisk Park 1
- Erica Nishimura
- Novo Nordisk A/S, Novo Nordisk Park 1
- Martin Münzel
- Novo Nordisk A/S, Novo Nordisk Park 1
- Christian Lehn Brand
- Novo Nordisk A/S, Novo Nordisk Park 1
- Carsten Enggaard Stidsen
- Novo Nordisk A/S, Novo Nordisk Park 1
- Christian Hove Claussen
- Novo Nordisk A/S, Novo Nordisk Park 1
- Erik Max Wulff
- Novo Nordisk A/S, Novo Nordisk Park 1
- Lone Pridal
- Novo Nordisk A/S, Novo Nordisk Park 1
- Ulla Ribel
- Novo Nordisk A/S, Novo Nordisk Park 1
- Jonas Kildegaard
- Novo Nordisk A/S, Novo Nordisk Park 1
- Trine Porsgaard
- Novo Nordisk A/S, Novo Nordisk Park 1
- Eva Johansson
- Novo Nordisk A/S, Novo Nordisk Park 1
- Dorte Bjerre Steensgaard
- Novo Nordisk A/S, Novo Nordisk Park 1
- Lars Hovgaard
- Novo Nordisk A/S, Novo Nordisk Park 1
- Tine Glendorf
- Novo Nordisk A/S, Novo Nordisk Park 1
- Bo Falck Hansen
- Novo Nordisk A/S, Novo Nordisk Park 1
- Maja Kirkegaard Jensen
- Novo Nordisk A/S, Novo Nordisk Park 1
- Peter Kresten Nielsen
- Novo Nordisk A/S, Novo Nordisk Park 1
- Svend Ludvigsen
- Novo Nordisk A/S, Novo Nordisk Park 1
- Susanne Rugh
- Novo Nordisk A/S, Novo Nordisk Park 1
- Patrick W. Garibay
- Novo Nordisk A/S, Novo Nordisk Park 1
- Mary Courtney Moore
- Vanderbilt University
- Alan D. Cherrington
- Vanderbilt University
- Thomas Kjeldsen
- Novo Nordisk A/S, Novo Nordisk Park 1
- DOI
- https://doi.org/10.1038/s41467-020-17487-9
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 9
Abstract
Recently, the first orally-administered ultra-long acting insulin was shown to have clinical efficacy. Here, the authors report the molecular engineering, as well as the biological and pharmacological properties of these insulin analogues.
